Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.
P/E ratio for Pear Therapeutics, Inc. (PEAR)
P/E ratio as of 2022: -6.89
According to Pear Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -6.89. At the end of 2021 the company had a P/E ratio of -34.62.
P/E ratio history for Pear Therapeutics, Inc. from 2019 to 2022
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2022 | -6.89 |
| 2021 | -34.62 |
| 2020 | -13.70 |
| 2019 | 111.21 |